INDEX TO VOLUME 3

AUTHOR INDEX

ANSBACHER, R., 209
BERGSTRÖM, S., 279
BERNSTEIN, G.S., 37
BIRK, S.A., 185
BOLOGNESE, R.J., 115
BRIGGS, M., 381
BRIGGS, M.H., 381
BUHI, W.C., 185
BUTLER, M., 347
CAMPBELL, C., 209
CLEMETSON, C.A.B., 269
CLINE, E.M., 261
COMHAIRE, F., 301
COREY, B., 21
CORSON, S.L., 115
DIKSHIT, S.S., 327
DORFMAN, R.I., 387
FELDMAN, J.G., 93, 313
FREEMAN, R.K., 121
GIANNINA, T., 347
GOULD, K.G., 261
GUNN, B.A., 401
HARTFIELD, V.J., 105
HEINEN, G., 45
JOHNSON, D., 55
JOSHI, S.G., 393, 401
JOSHI, U.M., 327
KARIM, S.M.M., 173
KAUFMAN, R.G., 121
KENNEDY, C., 387
KESSERÜ, E., 195
KORA, S.J., 327
KORBA, V.D., 415
LARRAÑAGA, A., 195
LAURIE, R.E., 415
LEE, C.H., 241
LOEWIT, K., 219
LONG, W.N., 21
LIPPES, J., 93, 313
MALLIKARJUNESWARA, V.R., 269
MC CALLA, K.O., 387
MC CREARY, S.A., 185
MISHELL, D.R., JR., 121
NEMSER, S., 115
POPICK, F., 347
PRASAD, M.R.N., 335
RAJALAKSHMI, M., 335
RAO, S.S., 327
RICE-WRAY, E., 137
RINDT, W., 45
ROOKS II, W.H., 387
SAROJA, N., 269
SCUTCHFIELD, F.D., 21
SIMMER, H.H., 1
SINGH, S.P., 335
SPELLACY, W.N., 185
SRIVASTAVA, P.N., 261
STEINETZ, B., 347
STURTEVANT, F.M., 133
SUN, T.H., 241
TYLER, C.W., JR., 21
UMLA, H., 45
VANDEWEGHE, M., 301
VERMEULEN, A., 301
VIRKAR, K.D., 327
WAIT, R.B., 133
WILLIAMS, W.L., 261
YEBOA, J., 45

INDEX TO VOLUME 3

SUBJECT INDEX

Abortifacient activity, prostaglandins, 121
Abortion effect, Warfarin (mice), 279
3-(acetonylbenzyl)-4-hydroxy-coumarin (Warfarin), 279
Acrosomes, 261
Aerosol contraceptive foam, clinical effectiveness, 37
Antibody formation, effect of steroidal contraceptives, 327
Anti-estrogenic contraceptives (rats and hamsters), 347
Antifertility agents, inhibition of fertilization (rabbits), 261
Antifertility agents, steroidal and nonsteroidal (rats and hamsters), 347
Anti-uterotrophic activity (rats and hamsters), 347
Arterial versus venous thromboembolism, oral contraceptives, 301
Ascorbic acid, effect by estrogens (Guinea pig), 269
BDDA-ME (dl-cis-Bisdehydrodoisynolic acid methyl ether), 387
BDDA-ME, oral antifertility activity (rat), 387
Biology of fertilization and implantation, symposium, 55
Birth control experience in Taiwan, 241
Blood glucose, effect of combination oral contraceptive on, 185
Breakthrough bleeding (BTB), 45
Carcinogenesis, side effects, steroid antifertility agents, 137
Cervical cytology and histology, combination oral contraceptive, 415
Cervical mucus, effect on sperm migration with different contraceptive methods, 195
Cervical mucus, effect on sperm penetration with oral contraceptives or IUD, 209
Chlormadinone acetate, 327
Chlormadinone acetate, continuous administration, 45
CN55, 945-27, 347
Combination oral contraceptive, cervical cytology and histology, 415
Combination oral contraceptive, effect on blood glucose and plasma insulin, 185
Combination oral contraceptive, effect on sperm penetration, 209
Combination oral contraceptive, norethisterone acetate and ethinylestradiol, 381
Combination oral contraceptive, ethynodiol diacetate and mestranol, 185, 241
Combination oral contraceptive, norgestrel and ethinylestradiol, 241, 327, 415
Combined oral contraceptive, 4-year comparison with sequential oral contraceptive, 93
Continuation rates between Loop D and oral contraceptives, 313
Copper, immobilization of spermatozoa, 219
$CuCl_3$, immobilization of spermatozoa, 219
Cyproterone acetate, effect on histology of epididymis (rat), 335
Decapacitation factor, 261
Depo-medroxyprogesterone acetate, injectable female contraceptive, 21
Diethylstilbestrol, 327, 347

Dimethisterone, 133
dl-cis-Bisdehydrodoisynolic acid methyl ether (BDDA-ME), 387
Endometrial macromolecules, effect of IUFB (baboon), 393
Epididymis (rat), effect of cyproterone acetate on histology, 335
Escape ovulation and unplanned pregnancy, sequential oral contraceptive, 133
Estradiol-17β, 347
Estrogen, effect on sperm migration, 195
Estrogenic contraceptives (rats and hamsters), 347
Estrogens, effect on ascorbic acid in plasma and blood vessels (Guinea pig), 269
Estrogens as antifertility hormones, history of hormonal contraception, 1
Ethinylestradiol (see also ethynyl estradiol)
Ethinylestradiol, 133, 327, 381, 415
Ethinylestradiol, effect on serum proteins, 381
Ethynodiol diacetate, 185, 241
17α-ethynyl-17β-acetoxy-estr-4ene-3-one (norethindrone acetate), 381
17α-ethynyl-1,3,5(10)-estratriene-3,17-β-diol (ethinylestradiol), 381
Ethynylestradiol (see also ethinylestradiol)
Ethynylestradiol, 241
17α-ethynyl estradiol, 347
F-6066, 347
Family planning programme, role of nurse, 105
$FeCl_3$, immobilization of spermatozoa, 219
Fellner, Otfried Otto, history of hormonal contraception, 1
Feminin (estrogenic material), 1
Fertilization, biology of, symposium, 55
Gonadotrophin inhibitory activity, BDDA-ME (rat), 387
History of hormonal contraception, 1
Hormonal contraception, history, 1
Hormonal sterilization, 1
Immobilization of spermatozoa with copper, 219
Immobilization of spermatozoa with iron, 219
Implantation, biology of, symposium, 55
Inhibition of fertilization with naturally occurring antifertility agents (rabbit), 261
Injectable female contraceptive, medroxyprogesterone acetate, 21
Iron, immobilization of spermatozoa, 219
IUD (see also IUFB)
IUD, 241
IUD, continuation rate compared with oral contraceptive, 313
IUD, Lippes loop, role of nurse, 105
IUD, Shell loop, 115
IUD, effect on sperm migration, 195
IUD, effect on sperm penetration, 209
IUFB (see also IUD)
IUFB, 393
IUFB (rat), 401

IUFB, effect on incorporation of acetate-^{14}C into endometrial macromolecules (baboon), 393
Lippes loop, role of nurse, 105
Long-acting parenteral female contraceptive agent, medroxyprogesterone acetate, 21
Loop D, continuation rate compared with oral contraceptives, 313
Medroxyprogesterone acetate, injectable female contraceptive, 21
Megestrol acetate, 327
MER-25, 347
Mestranol, 185, 195, 241, 269
Metabolic changes, side effects, steroid antifertility agents, 137
6α-methyl, 17-acetoxyprogesterone (medroxyprogesterone acetate), 21
Microdose, D-norgestrel, 195
Microdose, oral progestogen, 195
Neuraminidase (sperm), 261
Neuraminidase - like factor, 261
Nonsteroidal antifertility agents (rats and hamsters), 347
Norethindrone acetate, 381
Norethindrone enanthate, 195
Norgestrel, 241, 327, 415
D-norgestrel, 195
Nurse, role in family planning programme, 105
Once-a-month vaginal administration of prostaglandins for fertility control, 173
Oral contraceptives, continuation rate compared with Loop D, 313
Oral contraceptives, vascular incidents, 301
ORF-3858, 347
Plasma insulin, effect of combination oral contraceptive on, 185
Postcoital insertion of IUFB (rat), 401
Post-treatment pregnancies and progeny, side effects, steroid antifertility agents, 137
Progestogen, effect on sperm migration, 195
Prostaglandin E_2, 121, 173
Prostaglandin $F_{2\alpha}$ 121, 173
Prostaglandins, abortifacient activity of intravenous administration, 121
Prostaglandins, once-a-month vaginal administration for fertility control, 173
Sequential oral contraceptive, effect on sperm penetration, 209
Sequential oral contraceptive, escape ovulation and unplanned pregnancy, 133
Sequential oral contraceptive, ethinylestradiol and dimethisterone, 133
Sequential oral contraceptive, 4-year comparison with combined oral contraceptive, 93
Serum proteins, effect by ethinylestradiol, 381
Shell loop, IUD, 115
Side effects, steroid antifertility agents, 137
Side effects, steroid antifertility agents, carcinogenesis, 137
Side effects, steroid antifertility agents, interviewing techniques, 137
Side effects, steroid antifertility agents, metabolic changes, 137

Side effects, steroid antifertility agents, population differences, 137
Side effects, steroid antifertility agents, post-treatment pregnancy and progeny, 137
Side effects, steroid antifertility agents, psychological factors, 137
Side effects, steroid antifertility agents, thromboembolic disorders, 137
Side effects, steroid antifertility agents, unrelated to method, 137
Silastic capsule, release of cyproterone acetate, 335
Spermatozoa, immobilization with copper, 219
Spermatozoa, immobilization with iron, 219
Sperm migration, effect by IUD, 195
Sperm migration, effect by progestogen, 195
Sperm migration, effect by sequential estrogen, 195
Sperm migration, human cervical mucus with different contraceptive methods, 195
Sperm penetration, effect by combination oral contraceptive, 209
Sperm penetration, effect by IUD, 209
Sperm penetration, effect by sequential oral contraceptives, 209
Spermicidal agent, 37
Steroid antifertility agents, side effects associated with, 137
Steroidal antifertility agents (rats and hamsters), 347
Steroidal contraceptives, effect on antibody formation, 327
SU13320, 347
Therapeutic abortion, induced by prostaglandins, 121
Thromboembolic disorders, side effects, steroid antifertility agents, 137
U11, 555A, 347
Uterotrophic activity, BDDA-ME (rat), 387
Uterotrophic activity (rats and hamsters), 347
Vaginal administration, prostaglandins, once-a-month for fertility control, 173
Vaginal contraceptive foam, clinical effectiveness, 37
Vascular incidents and oral contraceptives, 301
Venous versus arterial thromboembolism, oral contraceptives, 301
Warfarin, 3-(acetonylbenzyl)-4-hydroxy-coumarin, 279